// App-Quantinova.ai

: Palivizumab: Is it cost effective to extend the vaccination period for patients at risk of severe respiratory syncytial virus infection?

Researchers

Presenter

  • Gemma Wilson

Principal Investigators

  • Louise Selby

  • Pravin Desai

Medical Centers

  • East Suffolk and North Essex NHS Foundation Trust,Ipswich,Regno Unito

  • Lister Hospital, East and North Hertfordshire NHS Foundation Trust, Stevenage, United Kingdom

  • Addenbrookes Hospital, Cambridge University Hospital, Cambridge, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Palivizumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved